Amol Akhade: OS difference in first line Cdk inhibitors plus AI, amongst Palbociclib, Ribociclib and abemaciclib in MBC
Amol Akhade, Senior Consultant Medical Oncologist and Hemato-oncologist at Suyog Cancer Clinics and Reliance Hospitals, shared on LinkedIn:
“There is no significant OS difference in first line Cdk inhibitors plus AI, amongst Palbociclib, Ribociclib and abemaciclib in MBC .
Real world evidence in ESMO Open
Drug is as good or as bad as trial design?
Are all Cdk inhibitors equal? ”
Dr. Amol Akhade is a senior consultant medical oncologist and hemato-oncologist at Suyog Cancer Clinics and Reliance Hospitals. He has received his super specialization training in hemato-oncology and medical oncology from Tata Memorial Hospital.
He specialises in chemotherapy for hematological cancers as well as solid tumors. He also specialises in allogenic and autologous bone marrow transplant.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023